WaveMan · Form 4
Poulton Stuart insider trades
> Search tickers & screens ⌘K
LIVE

Poulton Stuart insider trades

Poulton Stuart has filed 19 Form 4s with the SEC that we hold, all for Karyopharm Therapeutics Inc. (KPTI), as EVP, Chief Development Officer. Across all of them we count 0 purchases worth $0 and 17 sales worth $146.8K reported on Form 4. In the last 12 months: 0 purchases ($0) and 4 sales ($56.4K). The largest single trade was a sale of 5,101 shares of Karyopharm Therapeutics Inc. worth $48.0K, dated 2026-03-02. The first filing on our record is dated 2023-02-17 and the latest 2026-07-30.

Karyopharm Therapeutics Inc. (KPTI)

EVP, Chief Development Officer · 19 filings · 17 purchases and sales
Trade dateCodeSharesValue as filedFiled
2023-02-15S, sale reported on Form 48$262023-02-17
2023-02-15S, sale reported on Form 4196$6192023-02-17
2023-02-15S, sale reported on Form 45,665$18.1K2023-02-17
2023-07-28S, sale reported on Form 42,845$4.8K2023-08-01
2024-02-15S, sale reported on Form 45,748$7.6K2024-02-20
2024-02-15S, sale reported on Form 499$1392024-02-20
2024-02-29S, sale reported on Form 416,311$19.1K2024-03-04
2024-03-01S, sale reported on Form 46,155$7.4K2024-03-04
2024-07-30S, sale reported on Form 42,883$3.1K2024-07-31
2025-02-18S, sale reported on Form 45,914$3.7K2025-02-19
2025-03-04S, sale reported on Form 43,548$22.3K2025-03-06
2025-07-29S, sale reported on Form 4191$8352025-07-30
2025-09-15S, sale reported on Form 4401$2.6K2025-09-16
2026-02-17S, sale reported on Form 4378$3.3K2026-02-19
2026-03-02S, sale reported on Form 45,101$48.0K2026-03-03
2026-05-14S, sale reported on Form 4403$3.8K2026-05-15
2026-07-28S, sale reported on Form 4189$1.3K2026-07-30
Source

Counted from the Form 4 filings this reporting owner (SEC CIK 1942597) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.

Source: U.S. Securities and Exchange Commission (EDGAR) and other official government data · Updated 2026-10-12 · For informational purposes only, not investment advice.
Privacy · Terms